Keith-Harrison Dewedoff
Voorzitter bij Kaizen Bioscience LLC
Profiel
Keith-Harrison Dewedoff is currently the Chairman at Kaizen Bioscience LLC and the Chief Financial Officer at Ceptur Therapeutics, Inc. He previously worked as the Chief Financial Officer at Danforth Advisors LLC and Code Biotherapeutics, Inc. In 2023, he briefly served as the Chief Financial Officer at NLS Pharmaceutics Ltd.
Actieve functies van Keith-Harrison Dewedoff
Bedrijven | Functie | Begin |
---|---|---|
Kaizen Bioscience LLC
Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Voorzitter | - |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Financieel Directeur/CFO | - |
Eerdere bekende functies van Keith-Harrison Dewedoff
Bedrijven | Functie | Einde |
---|---|---|
NLS PHARMACEUTICS LTD. | Financieel Directeur/CFO | 01-09-2023 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Financieel Directeur/CFO | - |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Financieel Directeur/CFO | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NLS PHARMACEUTICS LTD. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Finance |
Kaizen Bioscience LLC
Kaizen Bioscience LLC Pharmaceuticals: MajorHealth Technology Kaizen Bioscience LLC operates as an American pharmaceutical company. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |